198 related articles for article (PubMed ID: 24238058)
1. Potential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer.
Gunda V; Cogdill AP; Bernasconi MJ; Wargo JA; Parangi S
Surgery; 2013 Dec; 154(6):1456-62; discussion 1462. PubMed ID: 24238058
[TBL] [Abstract][Full Text] [Related]
2. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine.
Sigalotti L; Fratta E; Coral S; Tanzarella S; Danielli R; Colizzi F; Fonsatti E; Traversari C; Altomonte M; Maio M
Cancer Res; 2004 Dec; 64(24):9167-71. PubMed ID: 15604288
[TBL] [Abstract][Full Text] [Related]
3. Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules.
Adair SJ; Hogan KT
Cancer Immunol Immunother; 2009 Apr; 58(4):589-601. PubMed ID: 18791715
[TBL] [Abstract][Full Text] [Related]
4. A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression.
Gunda V; Frederick DT; Bernasconi MJ; Wargo JA; Parangi S
Thyroid; 2014 Aug; 24(8):1241-50. PubMed ID: 24811699
[TBL] [Abstract][Full Text] [Related]
5. Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma.
Shi X; Chen X; Fang B; Ping Y; Qin G; Yue D; Li F; Yang S; Zhang Y
Biomed Pharmacother; 2019 Apr; 112():108632. PubMed ID: 30797153
[TBL] [Abstract][Full Text] [Related]
6. MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing.
Bao L; Dunham K; Lucas K
Cancer Immunol Immunother; 2011 Sep; 60(9):1299-307. PubMed ID: 21626030
[TBL] [Abstract][Full Text] [Related]
7. Expression spectrum and methylation-dependent regulation of melanoma antigen-encoding gene family members in pancreatic cancer cells.
Bert T; Lubomierski N; Gangsauge S; Münch K; Printz H; Prasnikar N; Robbel C; Simon B
Pancreatology; 2002; 2(2):146-54. PubMed ID: 12123095
[TBL] [Abstract][Full Text] [Related]
8. Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1.
Krishnadas DK; Bao L; Bai F; Chencheri SC; Lucas K
Tumour Biol; 2014 Jun; 35(6):5753-62. PubMed ID: 24584817
[TBL] [Abstract][Full Text] [Related]
9. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine.
Weber J; Salgaller M; Samid D; Johnson B; Herlyn M; Lassam N; Treisman J; Rosenberg SA
Cancer Res; 1994 Apr; 54(7):1766-71. PubMed ID: 7511051
[TBL] [Abstract][Full Text] [Related]
10. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation.
De Smet C; De Backer O; Faraoni I; Lurquin C; Brasseur F; Boon T
Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7149-53. PubMed ID: 8692960
[TBL] [Abstract][Full Text] [Related]
11. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.
Nucera C; Nehs MA; Nagarkatti SS; Sadow PM; Mekel M; Fischer AH; Lin PS; Bollag GE; Lawler J; Hodin RA; Parangi S
Oncologist; 2011; 16(3):296-309. PubMed ID: 21355020
[TBL] [Abstract][Full Text] [Related]
12. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells.
Wischnewski F; Pantel K; Schwarzenbach H
Mol Cancer Res; 2006 May; 4(5):339-49. PubMed ID: 16687489
[TBL] [Abstract][Full Text] [Related]
13. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter.
De Smet C; Lurquin C; Lethé B; Martelange V; Boon T
Mol Cell Biol; 1999 Nov; 19(11):7327-35. PubMed ID: 10523621
[TBL] [Abstract][Full Text] [Related]
14. Induction of MAGE-3 expression in lung and esophageal cancer cells.
Weiser TS; Ohnmacht GA; Guo ZS; Fischette MR; Chen GA; Hong JA; Nguyen DM; Schrump DS
Ann Thorac Surg; 2001 Jan; 71(1):295-301; discussion 301-2. PubMed ID: 11216765
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide.
Coral S; Parisi G; Nicolay HJ; Colizzi F; Danielli R; Fratta E; Covre A; Taverna P; Sigalotti L; Maio M
Cancer Immunol Immunother; 2013 Mar; 62(3):605-14. PubMed ID: 23138873
[TBL] [Abstract][Full Text] [Related]
16. Induction of MAGE genes in lymphoid cells by the demethylating agent 5-aza-2'-deoxycytidine.
Shichijo S; Yamada A; Sagawa K; Iwamoto O; Sakata M; Nagai K; Itoh K
Jpn J Cancer Res; 1996 Jul; 87(7):751-6. PubMed ID: 8698626
[TBL] [Abstract][Full Text] [Related]
17. The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors.
Coperchini F; Croce L; Denegri M; Awwad O; Ngnitejeu ST; Muzza M; Capelli V; Latrofa F; Persani L; Chiovato L; Rotondi M
Sci Rep; 2019 Mar; 9(1):4390. PubMed ID: 30867499
[TBL] [Abstract][Full Text] [Related]
18. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.
Salerno P; De Falco V; Tamburrino A; Nappi TC; Vecchio G; Schweppe RE; Bollag G; Santoro M; Salvatore G
J Clin Endocrinol Metab; 2010 Jan; 95(1):450-5. PubMed ID: 19880792
[TBL] [Abstract][Full Text] [Related]
19. Promoter hypomethylation and reactivation of MAGE-A1 and MAGE-A3 genes in colorectal cancer cell lines and cancer tissues.
Kim KH; Choi JS; Kim IJ; Ku JL; Park JG
World J Gastroenterol; 2006 Sep; 12(35):5651-7. PubMed ID: 17007017
[TBL] [Abstract][Full Text] [Related]
20. MAGED4 expression in glioma and upregulation in glioma cell lines with 5-aza-2'-deoxycytidine treatment.
Zhang QM; Shen N; Xie S; Bi SQ; Luo B; Lin YD; Fu J; Zhou SF; Luo GR; Xie XX; Xiao SW
Asian Pac J Cancer Prev; 2014; 15(8):3495-501. PubMed ID: 24870746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
